Navigation Links
BD Announces Results for Third Fiscal Quarter
Date:7/24/2008

eased by 20 percent over diluted earnings per share from continuing operations, excluding the specified item, of 98 cents for the third fiscal quarter of 2007. For the nine-month periods, diluted earnings per share from continuing operations of $3.34 for fiscal 2008 increased by 17 percent over comparable fiscal 2007 diluted earnings per share from continuing operations of $2.86, which exclude the specified items.

(Table 1) Three Months Ended June 30, Nine Months Ended June 30,

FY2008 FY2007 % Change FY2008 FY2007 % Change

Diluted EPS

from

Continuing

Operations: $1.18 $0.95 24% $3.34 $2.38 40%

Specified Items:

In-Process

Research and

Development

Charge - 0.03 (1) - 0.48 (2)

Diluted EPS from

Continuing

Operations

Excluding

Specified

Items: $1.18 $0.98 20% $3.34 $2.86 17%

(1) Represents the effect on diluted earnings per share from continuing

operations of the in-process research and development ("IPR&D") charge

recorded in the third quarter of fiscal 2007 related to the Plasso

Technology acquisition.

(2) Represents the effect on diluted earnings per share from continuing

operations of the IPR&D charges recorded in the third and first

quarters of fiscal 2007 related to the Plasso and TriPath

acquisitions, respectively.

Segment Results

In the BD Medical segment, worldwide revenues for the quarter were $1.016 billion, representing an increase of 15 percent from the prior year period. Pharmaceutical Systems and Diabetes Care products led revenue growth in the segment. For the nine-month period ended June 30, 2008, the BD Medical segment reported 12 percent r
'/>"/>

SOURCE BD (Becton, Dickinson and Company)
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. Gerbig Engineering Announces Availability of Cleanroom Utility Panel
2. The Palomino Group Announces Launch of Meeting Support Services Business Unit
3. Misys Announces Preliminary Results for the Year Ended 31 May 2008
4. Cardiome Announces Preferred Share Financing
5. Mercy Health Plans Announces New Name for Their Medicare Advantage Plans: Mercy Medicare Advantage
6. American Heart Associations Announces Call for Entries for Howard L. Lewis Achievement Award
7. The Risk Management and Patient Safety Institute Announces 2008/2009 Annual Risk Management Conference, Dates
8. Genesis Pharmaceuticals Announces New Board Member and Forms Committees
9. Fitness Equipment Retailer Fitness 4 Home Superstore Announces New Scottsdale Location
10. Fidelity National Financial, Inc. Announces Opening of Fidelity National Title de Mexico S.A. de C.V.
11. CIHR announces $4.4 million to improve mental health of Canadians
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...ble in French . , Montreal, January 8, 2009 ...ding major contribution from a team led by Dr. Joh...it de Montral and the Montreal Heart Institute, ha...for ulcerative colitis. The findings, published in...ng researchers closer to understanding the biologi...
(Date:1/8/2009)... at Oregon Health & Science University,s School of...at the nerve cells controlling heart rate and bloo...cally important for proper nervous system growth. ...in the prevention of Sudden Infant Death Syndrome ...ational Institutes of Health, SIDS is the leading ...
(Date:1/8/2009)... Davis Vision, Inc., headquartered ...al vice president of sales for its Northern divisi...rle will contribute to Davis Vision,s national new...ong asset to Davis Vision,s sales management team,...esident and chief marketing officer. "Mike brings ...
(Date:1/8/2009)...swire/ -- Susan Knapp Pinnas, a leader of provider...ve diversified healthcare,experience, has been na...the,company announced today. , As a member...ll be,responsible for advancing AvMed,s overall p...s of strong relationships and service excellence. ...
Breaking Medicine News(10 mins):Health News:Identification of genetic markers for ulcerative colitis could lead to treatment 2Health News:Identification of genetic markers for ulcerative colitis could lead to treatment 3Health News:OHSU School of Dentistry team discovers new molecule in blood-pressure control system 2Health News:Davis Vision, Inc. Names Michael Ehrle Divisional Vice President of Sales 2Health News:Susan Knapp Pinnas Named AvMed Health Plans' New Senior Vice President of Network 2
...has claimed the lives of at least 234 cattle and o...ax is caused by a spore-forming bacterium, shed by...l following flooding or high temperatures. It is o...e. In rare situations it can be transmitted to hum...
... the decision of the BSF to terminate the services...0 percent disability on account of contracting the...that the termination was being upheld on the groun...led due to the ailment and not because of his cont...
...he approval of US Food and Drug Administration (US...DA) for Meloxicam tablets used in the treatment of...approval is for Meloxicam tablets of strengths of ...any informed the Bombay Stock Exchange. "The appro...
...n users in US and South Africa practice unsafe sex...w study. // "Forty percent of the HIV-positive wom... partners, and more than half of the time, condoms...d author Dr. Mary H. Latka. The study is published...
Other Medicine News:
(Date:1/6/2009)...HCC for maintaining a healthy immune system , ,... published study in Nutrition and Cancer (60(5),...ity in Osaka, Japan has shown that AHCC (Active He... by increasing the number of dendritic cells (DCs)...ble for presenting foreign substances to other imm...
(Date:1/6/2009)...wire-USNewswire/ -- The Michael J. Fox Foundation ...stry research teams for pre-clinical research on p..., , The funding was awarded under the Foundation...gram, first launched in 2006, supports and bolster.... TDI is part of MJFF,s focus on ,de-risking, ...
(Date:1/6/2009)... Cequent Pharmaceuticals, a pionee...RNAi-based treatments to prevent and treat human d...mpleted a successful toxicology study of its candi...peutic targeting the primary oncogene (beta-cateni.... FAP is an inherited gastrointestinal disease tha...
(Date:1/6/2009)...ry 6 , - Early Re... Until,December 2011 , - Expansion of the ...scovery in Ophthalmology , - Revised Commer...blicenses to a Third Party , ExonHit Ther...forcement,of its existing drug discovery collabor...
Breaking Medicine Technology:Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells 2Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells 3Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinson's Disease Research 2Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference 2Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference 3ExonHit Therapeutics Expands Strategic Collaboration With Allergan 2ExonHit Therapeutics Expands Strategic Collaboration With Allergan 3ExonHit Therapeutics Expands Strategic Collaboration With Allergan 4Video 3A Insulet Unveils Video Contest for OmniPod Users 9134 1Video 3A Insulet Unveils Video Contest for OmniPod Users 9134 2Video 3A Insulet Unveils Video Contest for OmniPod Users 9134 3Gilead to Topple GSK as the Top Player in the Anti Infectives Drug Market in 2014 9132 1Gilead to Topple GSK as the Top Player in the Anti Infectives Drug Market in 2014 9132 2Gilead to Topple GSK as the Top Player in the Anti Infectives Drug Market in 2014 9132 3Golden Meditech Releases FY2008 09 Interim Results 29600 1Golden Meditech Releases FY2008 09 Interim Results 29600 2Golden Meditech Releases FY2008 09 Interim Results 29600 3Forterus Inc Announces Stock Buyback 29598 1Forterus Inc Announces Stock Buyback 29598 2
...NGTON, Mass.--(BUSINESS WIRE)--Jun 5, 2007 - Synta...ceutical company,focused on discovering, developin...at severe medical conditions, today announced,it w...y to discuss,these results, which will be presente... Clinical Oncology (ASCO) in Chicago, Illinois,thi...
...MANCHESTER, England - (5 June 2007) -,Phytopharm p...unces,today pre-clinical data showing that Cogane(...involved in Parkinson,s disease.,This data will be...ally recognised expert on Parkinson,s disease at ,...ease and Movement,Disorders, 5 June in Istanbul, T...
Other Medicine Technology:Cogane Data Presented at ‘11th International Congress of,Parkinson’s Disease and Disorders’ 2Cogane Data Presented at ‘11th International Congress of,Parkinson’s Disease and Disorders’ 3Cogane Data Presented at ‘11th International Congress of,Parkinson’s Disease and Disorders’ 4Cogane Data Presented at ‘11th International Congress of,Parkinson’s Disease and Disorders’ 5
...ity Biotech Captia™ Mumps IgG Enzyme-linked Im...ction and quantitative determination of IgG antibo...specimens may be used for the determination of imm...ay be used to demonstrate seroconversion or a sign...
The DSL-05-10-MUG Mumps IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit provides materials for the determination of IgG-class antibodies to Mumps Virus in human serum. This assay is intended for in
...nal treatment of diseases of the thoracic aorta ha...ision in the chest to place a synthetic graft to r...in long hospital stays and painful recoveries. Tod... alternatives to this major open surgical approach...
...lagship product, the Super Premium ALPHA 10 System... versatility in an intuitive and ergonomically des...tem for Perinatology/Maternal & Fetal Medicine Spe...ons, Breast Imaging, and General Imaging departmen...
Medicine Products: